ALL ) with the Abl-tyrosine kinase inhibitor STI 571 ( Glivec ) + leukemia ( Ph Philadelphia chromosome / Bcr-Bbl positive acute lymphoblastic Early minimal residual disease ( MRD ) analysis during treatment

word count: 250 Text body word count: 4915 Copyright 2002 American Society of Hematology Blood First Edition Paper, prepublished online August 22, 2002; DOI 10.1182/blood-2002-02-0360 only. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From

[1]  Sante Tura,et al.  A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.

[2]  D. Hoelzer,et al.  Recent approaches in acute lymphoblastic leukemia in adults. , 2002, Critical reviews in oncology/hematology.

[3]  S. de Vos,et al.  Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. , 2002, Blood.

[4]  T. Lipp,et al.  Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. , 2002, Blood.

[5]  David Elashoff,et al.  Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study , 2002, The Lancet.

[6]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[7]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[8]  H. Mano,et al.  In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. , 2001, Blood.

[9]  J. Topaly,et al.  Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells , 2001, Leukemia.

[10]  N. Goulden,et al.  Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia , 2001, British journal of haematology.

[11]  J. Radich Philadelphia chromosome-positive acute lymphocytic leukemia. , 2001, Hematology/oncology clinics of North America.

[12]  Z. Estrov,et al.  Studies of minimal residual disease in acute lymphocytic leukemia. , 2000, Hematology/oncology clinics of North America.

[13]  T. Lipp,et al.  Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). , 2000, Hematology/oncology clinics of North America.

[14]  K. Kolibaba,et al.  Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. , 2000, Blood.

[15]  E. Macintyre,et al.  Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease , 1999, Leukemia.

[16]  U. Jaeger,et al.  Quantification of minimal residual disease in patients with BCR‐ABL‐positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction , 1999, British journal of haematology.

[17]  George Q. Daley,et al.  The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity , 1999, The Journal of experimental medicine.

[18]  L. Foroni,et al.  INVESTIGATION OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD AND ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA BY MOLECULAR ANALYSIS , 1999, British journal of haematology.

[19]  J. Hancock,et al.  Minimal Residual Disease Status Before Allogeneic Bone Marrow Transplantation Is an Important Determinant of Successful Outcome for Children and Adolescents With Acute Lymphoblastic Leukemia , 1998 .

[20]  W. Hop,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[21]  H. Cavé,et al.  Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .

[22]  J. Hancock,et al.  Minimal residula disease status as a predictor of relapse after allogenic bone marrow transplantation for children with acute lymphoblastic leukaemia , 1998, British journal of haematology.

[23]  A. Morley,et al.  Monitoring minimal residual disease in peripheral blood in B‐lineage acute lymphoblastic leukaemia , 1997, British journal of haematology.

[24]  L. Foroni,et al.  Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response , 1997, Leukemia.

[25]  P. Sykes,et al.  Effect of the Philadelphia chromosome on minimal residual disease in acute lymphoblastic leukemia , 1997, Leukemia.

[26]  J. Radich,et al.  Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. , 1997, Blood.

[27]  C. Preudhomme,et al.  Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL) , 1997, Leukemia.

[28]  A. Morley,et al.  Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. , 1996, Blood.

[29]  J. Goldman,et al.  Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. , 1995, Leukemia.

[30]  A. Morley,et al.  Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction , 1994, The Lancet.

[31]  K. Sikora,et al.  Leukemia , 1984, British Journal of Cancer.

[32]  R. Larson,et al.  Acute Lymphocytic Leukemia in Adults , 2000 .

[33]  J. V. van Dongen,et al.  Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. , 1992, Leukemia.